INCA036978 (novel investigational agent for MPN)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-15 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms: Phase 1 dose-escalation/expansion trial registered to evaluate INCA036978 as monotherapy and in combination with standard disease-directed therapy in MPN patients, with primary endpoints of safety, tolerability, DLTs, MTD, and recommended expansion dose (trial-early; no efficacy or safety readouts yet). (novelty: 4)
Open questions
Related
Contributing findings
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
15-apr-2026
novelty 4
per-area 4
introduces